Nippon Chemiphar Sees Profits Halved
Sales Drop 4% Due To Japanese NHI Drug Price Revisions
Japanese NHI drug price revisions implemented in October 2019 are responsible for operating profits halving amid declining sales and future uncertainty, Nippon Chemiphar said as it slashed its full-year forecast.
You may also be interested in...
Despite the delay in a New York state opioid trial due to coronavirus, a motion has been filed to remove Mallinckrodt and SpecGx from proceedings. However, Nassau County opposed the motion.
Alvotech has partnered with DKSH to bring its high-concentration Humira rival to Asia. The Alvogen sister company plans to file the adalimumab biosimilar with the EMA and FDA in the second half of 2020.
The Indian Pharmaceutical Alliance is working closely with the World Health Organization and International Generic and Biosimilar Medicines Association, as well as regional off-patent industry bodies in the US and Europe, to “navigate challenges on the manufacturing and logistics front” due to the coronavirus pandemic. Meanwhile, the IPA has welcomed domestic initiatives to boost API manufacturing.